Antibody specific to spike protein of sars-cov-2 and uses thereof
US-2023279080-A1 · Sep 7, 2023 · US
Recombinant virus, composition comprising the same, and uses thereof
US12085340B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12085340-B2 |
| Application number | US-202217933832-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 20, 2022 |
| Priority date | Nov 8, 2016 |
| Publication date | Sep 10, 2024 |
| Grant date | Sep 10, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.
First claim
Opening claim text (preview).
What is claimed is: 1. A recombinant Influenza A virus (IAV), comprising: a mutant neuraminidase (NA), which, as compared with its wild-type counterpart, consists of the amino acid sequence of SEQ ID NO: 11, 12 or 13; wherein the mutant NA is defective in neuraminidase activity. 2. An immunogenic composition, comprising (i) a recombinant Influenza A virus (IAV) of claim 1 ; and (ii) a pharmaceutically acceptable carrier. 3. The immunogenic composition of claim 2 , wherein the pharmaceutically acceptable carrier is an adjuvant. 4. A method for inducing immune responses against influenza A virus in a subject, the method comprising administering to a subject in need thereof an effective amount of the immunogenic composition of claim 2 . 5. The method of claim 4 , wherein the subject is a human subject. 6. The method of claim 5 , wherein the human subject is infected, suspected of being infected, or at risk for infection by an influenza A virus. 7. The method of claim 6 , wherein the influenza A virus is an H1N1 or H5N1 influenza A virus. 8. The method of claim 4 , wherein the immunogenic composition is administered to the subject via a route selected from the group consisting of oral administration, enteral administration, nasal administration, topical administration, and transmucosal administration. 9. The method of claim 4 , wherein the immunogenic composition is administered to the subject parenterally.
Assignees
Inventors
Classifications
with the parallel tube parts close to each other, e.g. a serpentine · CPC title
Heating by electric discharge, e.g. arc discharge · CPC title
Cooling arrangements · CPC title
Viral antigens · CPC title
Preparations for testing in vivo · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12085340B2 cover?
- Immunogenic compositions comprising hemagglutinin (HA) variants and/or neuraminidase (NA) variants, which may be contained in an influenza A virus, and uses thereof for eliciting immune responses against influenza A virus.
- Who is the assignee on this patent?
- Academia Sinica
- What technology area does this patent fall under?
- Primary CPC classification F27D1/12. Mapped technology areas include Mechanical Engineering.
- When was this patent published?
- Publication date Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).